Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate

This publication has 49 references indexed in Scilit:

• Are G3 ENETS neuroendocrine neoplasms heterogeneous?
  Endocrine-Related Cancer, 2013
• Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
  Annals of Oncology, 2012
• AKT/mTOR as Novel Targets of Polyphenol Piceatannol Possibly Contributing to Inhibition of Proliferation of Cultured Prostate Cancer Cells
  ISRN Urology, 2012
• Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
  Cancer Discovery, 2011
• Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
  Annals of Oncology, 2011
• Paraneoplastic syndromes in prostate cancer
  Nature Reviews Urology, 2010
• Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features
  Annals of Oncology, 2009
• Small cell carcinoma of the prostate treated with amrubicin
  International Journal of Clinical Oncology, 2008
• Docetaxel and Cisplatin in Patients With Metastatic Androgen Independent Prostate Cancer and Circulating Neuroendocrine Markers
  Journal of Urology, 2007
• Small cell carcinoma of prostate: Effectiveness of hormonal versus chemotherapy
  Urology, 1992